Image Sourced ShutterStock
The Market Herald - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • RotoGro is expanding its global presence following the purchase of Canadian company Supra THC and the distribution of its ‘Garden’ technology across North America, Europe and Australasia
  • RotoGro’s share price hasn’t changed from previous close. It currently sits at $0.15 per share.

RotoGro is focusing on increasing its global presence as a cultivator of legal cannabis.

Following the purchase of Canadian medical cannabis testers, Supra THC, the company is looking to expand its business.

Supra THC obtained a dealers license from Health Canada. The license gives the company approval to conduct standard processing, analytical testing, research, production and sales and distribution of lawful cannabis.

As RotoGro works to increase its presence in Canada, the company is looking at becoming dually listed on the Canadian Securities Exchange (CSE).

In addition the being listed on the ASX, RotoGro is also listed on Germany’s Frankfurt Stock Exchange.

According to the company, being listed on the CSE exposes it to the largest capital market for cannabis focused companies globally.

RotoGro’s Garden technology has been successful in reducing operation costs and improving product consistency.

The tech triples growing space while occupying the same space as a regular flat deck table, significantly increasing the amount of cannabis grown in a given time frame.

RotoGro receive revenue from selling its Garden technology to other companies growing cannabis and agricultural businesses.

The company’s technology is being delivered across North America, Europe and Australasia.

RotoGro’s share price hasn’t changed from previous close. It currently sits at $0.15 per share.

RGI by the numbers
More From The Market Herald

The Calmer Co locks in $700k in funding via convertible note issue

The Calmer Co (ASX:CCO) has confirmed its receipt of $700,000 in funding from existing shareholders.

FDA greenlights Botanix Pharmaceuticals’ Sofdra resubmission plan

FDA approves Botanix's strategy for Sofdra NDA resubmission with no additional materials requested, keeping submission to…

Botanix Pharmaceuticals successfully closes $13.5m Placement to boost US commercial activities

Botanix Pharmaceuticals (ASX: BOT) has closed its $13.5 million placement to both new and existing institutional…

Pharmaust completes Phase One Monepantel study and files for Orphan Drug Designation

Pharmaust (ASX:PAA) has announced that all patients have completed its phase one MEND study using monepantel…